123 related articles for article (PubMed ID: 361222)
1. Phase I study of methanesulfonamide, N-[4-(9-acridinylamino)-3-methoxyphenyl]-(m-AMSA) using a single-dose schedule.
Von Hoff DD; Howser K; Gormley P; Bender RA; Glaubiger D; Levine AS; Young RC
Cancer Treat Rep; 1978 Oct; 62(10):1421-6. PubMed ID: 361222
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical and pharmacological study of 4'-(9-acridinylamino)-methanesulfon-m-anisidide using an intermittent biweekly schedule.
Van Echo DA; Chiuten DF; Gormley PE; Lichtenfeld JL; Scoltock M; Wiernik PH
Cancer Res; 1979 Oct; 39(10):3881-4. PubMed ID: 476624
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 clinical investigation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992), a new acridine derivative.
Legha SS; Gutterman JU; Hall SW; Benjamin RS; Burgess MA; Valdivieso M; Bodey GP
Cancer Res; 1978 Nov; 38(11 Pt 1):3712-6. PubMed ID: 279397
[TBL] [Abstract][Full Text] [Related]
4. Phase I evaluation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) by a weekly iv dose schedule.
Woodcock TM; Schneider RJ; Young CW
Cancer Treat Rep; 1980 Jan; 64(1):53-5. PubMed ID: 6892893
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of triglycidylurazol given on a 5-day i.v. schedule.
Nicaise C; Rozencweig M; Crespeigne N; Dodion P; Gerard B; Lambert M; Decoster G; Kenis Y
Cancer Treat Rep; 1986 May; 70(5):599-603. PubMed ID: 3708609
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of chlorozotocin.
Gralla RJ; Tan CT; Young CW
Cancer Treat Rep; 1979 Jan; 63(1):17-20. PubMed ID: 154363
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
Arteaga CL; Brown TD; Kuhn JG; Shen HS; O'Rourke TJ; Beougher K; Brentzel HJ; Von Hoff DD; Weiss GR
Cancer Res; 1989 Aug; 49(16):4648-53. PubMed ID: 2743343
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride with correlative in vitro human tumor clonogenic assay.
Alberts DS; Mackel C; Pocelinko R; Salmon SE
Cancer Res; 1982 Mar; 42(3):1170-5. PubMed ID: 7037174
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of maytansine using a 3-day schedule.
Cabanillas F; Rodriguez V; Hall SW; Burgess MA; Bodey GP; Freireich EJ
Cancer Treat Rep; 1978 Mar; 62(3):425-8. PubMed ID: 348310
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934).
LoRusso P; Foster BJ; Poplin E; McCormick J; Kraut M; Flaherty L; Heilbrun LK; Valdivieso M; Baker L
Clin Cancer Res; 1995 Dec; 1(12):1487-93. PubMed ID: 9815948
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of 4'-(9-acridinylamino) methanesulfon-m- anisidide (AMSA) in metastatic melanoma.
Legha SS; Hall SW; Powell KC; Burgess MA; Benjamin RS; Gutterman JU; Bodey GP
Cancer Clin Trials; 1980; 3(2):111-4. PubMed ID: 6893573
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of SOAz.
Nasca S; Jezekova D; Coninx P; Garbe E; Carpentier Y; Cattan A
Cancer Treat Rep; 1982 Dec; 66(12):2039-42. PubMed ID: 7139646
[TBL] [Abstract][Full Text] [Related]
14. [Phase I-II studies of a new antineoplastic agent, 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA)].
Horikoshi N; Ogawa M; Inagaki J; Ezaki K; Inoue K; Okabe K; Nagata T; Aiba K; Domyo M
Gan To Kagaku Ryoho; 1982 Feb; 9(2):244-9. PubMed ID: 6897858
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of arabinofuranosyl-5-azacytosine (fazarabine, NSC 281272).
Surbone A; Ford H; Kelley JA; Ben-Baruch N; Thomas RV; Fine R; Cowan KH
Cancer Res; 1990 Feb; 50(4):1220-5. PubMed ID: 1688736
[TBL] [Abstract][Full Text] [Related]
16. Phase I-II study of m-AMSA administered as a continuous infusion.
Micetich KC; Zwelling LA; Gormley P; Young RC
Cancer Treat Rep; 1982 Oct; 66(10):1813-7. PubMed ID: 6897013
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of mitoxantrone by 24-hour continuous infusion.
Anderson KC; Garnick MB; Meshad MW; Cohen GI; Pegg WJ; Frei E; Israel M; Modest E; Canellos GP
Cancer Treat Rep; 1983 May; 67(5):435-8. PubMed ID: 6850662
[TBL] [Abstract][Full Text] [Related]
18. [Phase I study of CI-898. CI-898 Study Group].
Taguchi T; Tsukagoshi S; Furue H; Niitani H; Ohta K; Ariyoshi H; Hasegawa K; Majima H; Nakao I; Yasutomi M
Gan To Kagaku Ryoho; 1991 Aug; 18(10):1599-612. PubMed ID: 1831340
[TBL] [Abstract][Full Text] [Related]
19. [The clinical phase I study of TNP-351. The TNP-351 Research Committee].
Taguchi T; Niitani H; Furue H; Tsukagoshi S; Kanamaru R; Hasegawa K; Akazawa S; Yoneda S; Tominaga T; Sasaki T
Gan To Kagaku Ryoho; 1995 Feb; 22(2):259-71. PubMed ID: 7857102
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine).
Judson IR; Calvert AH; Rutty CJ; Abel G; Gumbrell LA; Graham MA; Evans BD; Wilman DE; Ashley SE; Cairnduff F
Cancer Res; 1989 Oct; 49(19):5475-9. PubMed ID: 2670205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]